Back to Search
Start Over
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
- Source :
- Bone Marrow Transplantation, 56, 2445-2453, Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩, Bone Marrow Transplantation, 56, 10, pp. 2445-2453, Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
- Publication Year :
- 2021
-
Abstract
- Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1−) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1−) months. Survival rates showed no difference between RUNX1+ and RUNX1− patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p = 0.7; 2-year LFS: 61.1 vs. 60.8%, p = 0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.
- Subjects :
- Oncology
YOUNGER
Multivariate analysis
Transplantation Conditioning
PROGNOSIS
IMPACT
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
[SDV]Life Sciences [q-bio]
Medizin
Graft vs Host Disease
Gene mutation
DISEASE
chemistry.chemical_compound
0302 clinical medicine
hemic and lymphatic diseases
ADULT PATIENTS
Acute leukemia
Incidence (epidemiology)
Remission Induction
Hematopoietic Stem Cell Transplantation
Myeloid leukemia
Hematology
3. Good health
[SDV] Life Sciences [q-bio]
Leukemia, Myeloid, Acute
RUNX1
030220 oncology & carcinogenesis
Core Binding Factor Alpha 2 Subunit
embryonic structures
medicine.medical_specialty
ACUTE MYELOID-LEUKEMIA
DIAGNOSIS
Article
Acute myeloid leukaemia
03 medical and health sciences
Internal medicine
medicine
Humans
ddc:610
Aged
Retrospective Studies
Transplantation
business.industry
Stem-cell therapies
Minimal residual disease
GENE
chemistry
Mutation
business
030215 immunology
Subjects
Details
- ISSN :
- 02683369
- Database :
- OpenAIRE
- Journal :
- Bone Marrow Transplantation, 56, 2445-2453, Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩, Bone Marrow Transplantation, 56, 10, pp. 2445-2453, Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
- Accession number :
- edsair.doi.dedup.....4cb9bd24eca641c014554135ee74ff3b